RecruitingNot Applicable

Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer

Hong Kong94 participantsStarted 2023-11-10

Plain-language summary

Patients with unresectable pancreatic cancer are often demoralized by intractable, persistent and incapacitating pain. It must be managed aggressively and strong opioids are recommended as the mainstay of treatment. However, patients develop opioid-related adverse effects. EUS-guided celiac plexus neurolysis (CPN) and celiac ganglion neurolysis (CGN) has been shown to provide high efficacy for pain control. The optimal timing, however, is in debate.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \>= 18 years old
✓. Diagnosed to have inoperable pancreatic cancer
✓. Presence of tumor pain (centrally located, constant, with no other obvious cause) with a VAS \>= 3
✓. Karnofsky performance status \>= 60
✓. Planned for EUS examination and/or biopsy of the pancreatic tumor

Exclusion criteria

✕. Allergy to bupivacaine, or alcohol
✕. Potentially operable after neoadjuvant therapy
✕. Expected survival of less than 3 months
✕. Patient who is already on opioids for pain control
✕. Previous percutaneous or EUS-guided CGN/ CPN
✕. Recurrent pancreatic tumors after operation
✕. Uncorrectable coagulopathy
✕. Inability or unwillingness to provide informed consent

What they're measuring

The mean change in VAS pain score at 3 months

Timeframe: 3 months

Trial details

NCT IDNCT06160323

SponsorChinese University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-07-31

Contact for this trial

Shannon Melissa Chan

852-35052627 shannonchan@surgery.cuhk.edu.hk

View on ClinicalTrials.gov More Pancreatic Cancer Non-resectable trials